Clinitech Laboratory Limited IPO: Analysis, GMP & Subscription Status

Introduction

Clinitech Laboratory Limited, a prominent player in the diagnostics and laboratory sector, is set to launch its Initial Public Offering (IPO) from July 25, 2024, to July 29, 2024. This IPO presents an opportunity for investors to participate in the growth and expansion of the company.

IPO Timeline

• IPO Open Date: Thursday, July 25, 2024
• IPO Close Date: Monday, July 29, 2024
• Basis of Allotment: Tuesday, July 30, 2024
• Initiation of Refunds: Wednesday, July 31, 2024
• Credit of Shares to Demat: Wednesday, July 31, 2024
• Listing Date: Thursday, August 1, 2024
• Cut-off time for UPI mandate confirmation: 5 PM on July 29, 2024

IPO Details

• Face Value: ₹10 per share
• Price: ₹96 per share
• Lot Size: 1200 Shares
• Total Issue Size: 602,400 shares (aggregating up to ₹5.78 Cr)
• Fresh Issue: 602,400 shares (aggregating up to ₹5.78 Cr)
• Issue Type: Fixed Price Issue IPO
• Listing At: BSE SME
• Shareholding Pre-Issue: 1,680,000 shares
• Shareholding Post-Issue: 2,282,400 shares
• Market Maker Portion: 31,200 shares by Bhh Securities

Clinitech Laboratory Limited Financial Performance (₹ in Lakhs)

Key Strengths

1. Experienced Promoters and Management Team: The promoters of Clinitech Laboratory Limited possess significant in-depth knowledge of the laboratory and diagnostics industry and have been instrumental in the consistent growth of the company’s performance. Their vast experience in the industry is a strong foundation for the company's future growth.

2. Strong Client Relationships: The company has maintained robust relationships with its clients by consistently meeting their needs and ensuring timely delivery, leading to repeat orders and customer loyalty.

Risks

1. Market Risks: The company’s operations and profitability are susceptible to market risks, including price fluctuations, changes in government policies, and economic conditions.

2. Competition: The diagnostics and laboratory sector is highly competitive with numerous organized and unorganized players. Clinitech Laboratory's ability to maintain its market position depends on offering quality services at competitive prices.

3. Regulatory Risks: Changes in regulatory policies and compliance requirements can impact the company’s operations and profitability. Adhering to stringent environmental norms involves significant costs for pollution control and sustainable practices.

Clinitech Laboratory IPO GMP & Subscription Status

Stay updated with the latest information on the Clinitech Laboratory Limited IPO Grey Market Premium (GMP) and Subscription Status as they become available post-IPO opening. This section will be regularly updated with the latest GMP and subscription figures to help investors make informed decisions.

Grey Market Premium (GMP)

Subscription Status [times]

How to Apply

Investors can apply for the Clinitech Laboratory Limited IPO through ASBA (Applications Supported by Blocked Amount) in designated banks, or through UPI (Unified Payments Interface) for retail investors. Ensure to complete the application before the closing date to avoid any last-minute issues.

Conclusion

The Clinitech Laboratory Limited IPO presents a promising opportunity for investors, given the company’s strong market presence, experienced management, and consistent financial performance. However, potential investors should consider the associated risks and perform due diligence before investing.

For more details, refer to the DRHP of Clinitech Laboratory Limited.

Headlines:

1. "Clinitech Laboratory Limited IPO: Key Details, Financials, and Subscription Info"
2. "Clinitech Laboratory Limited IPO Launch: All You Need to Know About Dates, Price Band, and More"
3. "Investing in Clinitech Laboratory Limited IPO: Comprehensive Analysis and Financial Overview"
4. "Clinitech Laboratory Limited IPO Guide: Subscription Dates, Price Band, and Financial Insights"
5. "Upcoming Clinitech Laboratory Limited IPO: Detailed Financial Summary and Subscription Updates"